Treatment Resistant Depression - Global Clinical Trials Review H2, 2019

DUBLIN, Jan. 13, 2020 /PRNewswire/ -- The "Treatment Resistant Depression Global Clinical Trials Review, H2, 2019" clinical trials has been added to ResearchAndMarkets.com's offering.

This clinical trial report provides an overview of Treatment Resistant Depression clinical trials scenario.

Report Scope

• The report provides a snapshot of the global clinical trials landscape
• The report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
• The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
• The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
• The report provides enrollment trends for the past five years
• The report provides latest news for the past three months

Latest Clinical Trials News

• Oct 15, 2019: Relmada Therapeutics announces top-line results from REL-1017 phase 2 study in individuals with treatment resistant depression
• Oct 14, 2019: Relmada Therapeutics to announce results of phase 2 study of REL-1017 for treatment resistant depression and conduct Conference Call

Reasons to Buy

• Assists in formulating key business strategies with regards to investment
• Helps in identifying prominent locations for conducting clinical trials which saves time and cost
• Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
• Supports understanding of trials count and enrollment trends by country in global therapeutics market
• Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
• Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered

Companies Mentioned

• Johnson & Johnson
• F. Hoffmann-La Roche Ltd
• AstraZeneca plc
• Bristol-Myers Squibb Co
• Eli Lilly & Co
• Alkermes plc
• The Lundbeck Foundation
• Evotec SE
• Relmada Therapeutics Inc
• BrainCells Inc

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/hdtgpt

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/treatment-resistant-depression---global-clinical-trials-review-h2-2019-300985836.html

SOURCE Research and Markets